RxDoctor Payments Data

Stephanie Sanchez

Nurse Practitioner · Ormond Beach, FLNPI 1003130592

Payments from drug & device makers

$2,657in general payments, 2019–2025

Across 93 payments — averaging $28.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$517
  • Novo Nordisk$467
  • Bayer$244
  • Johnson & Johnson$198
  • Renalytix AI, Inc.$149
  • Amgen$142
  • plus $940 from 20 others

What the payments were for

  • Food & beverage$2,657100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,657 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$76,403
Medicare patients
160
Services billed
1,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide103$180,664
OzempicSemaglutide49$104,298
EliquisApixaban61$91,636
JardianceEmpagliflozin27$38,661
XareltoRivaroxaban24$33,725
JanuviaSitagliptin Phosphate22$27,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$24,324
EntrestoSacubitril/Valsartan16$14,221
Breo ElliptaFluticasone/Vilanterol20$13,478
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$10,877
Tresiba Flextouch U-100Insulin Degludec13$10,808
Atorvastatin Calcium605$6,033
MyrbetriqMirabegron13$5,973
Clonidine22$4,162
Albuterol Sulfate HfaAlbuterol Sulfate132$3,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$68$180,664103 claims
Novo NordiskOzempic$467$104,29849 claims
Boehringer IngelheimJardiance$21$38,66127 claims
Johnson & JohnsonXarelto$198$33,72524 claims
AbbVieSynthroid$517$99612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Ormond Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →